Reduction of relapses of atopic dermatitis with methylprednisolone aceponate cream twice weekly in addition to maintenance treatment with emollient: A multicentre, randomized, double-blind, controlled study

British Journal of Dermatology

Volumn 158, Issue 4, 2008, Pages 801-807

  Peserico, A ^a   Stadtler G ^b   Sebastian, M ^c   Fernandez, R Suarez ^d   Vick, K ^b   Bieber, T ^e  

^a UNIVERSITY OF PADOVA   (Italy)

^b Intendis GmbH   (Germany)

^c Group Practice   (Germany)

^d HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^e UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

Atopic dermatitis; Corticosteroid; Maintenance treatment; Methylprednisolone aceponate; Relapse

Indexed keywords

ADVABASE; ANTIHISTAMINIC AGENT; EMOLLIENT AGENT; GLUCOCORTICOID; METHYLPREDNISOLONE ACEPONATE; PIMECROLIMUS; PLACEBO; TACROLIMUS; UNCLASSIFIED DRUG; VACCINE;

ADD ON THERAPY; ADULT; ARTICLE; ATOPIC DERMATITIS; BACTERIAL INFECTION; BODY SURFACE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; LONG TERM CARE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; MYCOSIS; PATIENT ASSESSMENT; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; RELAPSE; SKIN BURNING SENSATION; SKIN IRRITATION; STRIA; TELANGIECTASIA; VIRUS INFECTION; VISUAL DISORDER;

ADOLESCENT; ADULT; ANTI-INFLAMMATORY AGENTS; CHILD; DERMATITIS, ATOPIC; DRUG ADMINISTRATION SCHEDULE; EMOLLIENTS; FEMALE; HUMANS; MALE; METHYLPREDNISOLONE; RECURRENCE; TREATMENT OUTCOME;

EID: 40949107967     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2008.08436.x     Document Type: Article

References (29)

1. Herd RM, Tidman MJ, Prescott RJ, Hunter JA. Prevalence of atopic eczema in the community: the Lothian Atopic Dermatitis study. Br J Dermatol 1996 135 : 18 19.
2. Levy RM, Gelfand JM, Yan AC. The epidemiology of atopic dermatitis. Clin Dermatol 2003 21 : 109 15.
3. Hoare C, Li Wan Po A, Williams H. Systematic review of treatments for atopic eczema. Health Technol Assess 2000 4 : 1 191.
4. Darsow U, Lübbe J, Taieb A et al. Position paper on diagnosis and treatment of atopic dermatitis. J Eur Acad Dermatol Venerol 2005 19 : 186 95.
5. Thomas KS, Armstrong S, Avery A et al. Randomised controlled trial of short bursts of a potent topical corticosteroid versus prolonged use of mild preparation for children with mild to moderate atopic eczema. BMJ 2002 324 : 768 71.
6. Hanifin JM, Cooper KD, Ho VC et al. Guidelines for care of atopic dermatitis. JAAD 2004 50 : 391 404.
7. Akdis CA, Akdis M, Bieber T et al. Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRATALL Consensus Report. Allergy 2006 64 : 969 87.
8. Luger TA, Loske KD, Elsner P et al. Topical dermatological therapy with glucocorticoids - therapeutic index. JDDG 2004 2 : 629 34.
9. Ruzicka T. Methylprednisolone aceponate in eczema and other inflammatory skin disorders - a clinical update. Int J Clin Pract 2006 60 : 85 92.
10. Bieber T, Vick K, Fölster-Holst R et al. Efficacy and safety of methylprednisolone aceponate ointment 0.1% compared to tacrolimus 0.03% in children and adolescents with an acute flare of atopic dermatitis. Allergy 2007 62 : 184 9.
11. Hanifin JM, Thurston M, Omoto M et al. The eczema and severity index (EASI): assessment of reliability in atopic dermatitis. Exp Dermatol 2001 10 : 11 18.
12. Eichenfeld LF, Lucky AW, Boguniewicz M et al. Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. J Am Acad Dermatol 2002 46 : 495 504.
13. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) - a simple practical measure for routine clinical use. Clin Exp Dermatol 1994 19 : 210 16.
14. Lewis-Jones MS, Finlay AY. The Children's Dermatology Life Quality Index (CDLQI): initial validation and practical use. Br J Dermatol 1995 132 : 942 9.
15. Berth-Jones J, Damstra RJ, Golsch S et al. Twice weekly fluticasone propionate added to emollient maintenance treatment to reduce risk of relapse in atopic dermatitis: randomised, double blind, parallel group study. BMJ 2007 326 : 1367 73.
16. Strid J, Strobel S. Skin barrier dysfunction and systemic sensitization to allergens through the skin. Curr Drug Targets Inflamm Allergy 2005 4 : 531 41.
17. Palmer CNA, Irvine AD, Terron-Kwiatkowski A et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet 2006 38 : 441 6.
18. Weidinger S, Illig T, Baurecht H et al. Loss-of-function variations within the filaggrin gene predispose for atopic dermatitis within allergic sensitizations. J Allergy Clin Immunol 2006 118 : 214 19.
19. Morar N, Cookson WO, Harper JI, Moffatt MF. Filaggrin mutations in children with severe atopic dermatitis. J Invest Dermatol 2007 127 : 1667 72.
20. Weidinger S, Rodríguez E, Stahl C et al. Filaggrin mutations strongly predispose to early-onset and extrinsic atopic dermatitis. J Invest Dermatol 2007 127 : 724 6.
21. van der Meer JB, Glazenburg EJ, Mulder PG et al. Management of moderate to severe atopic dermatitis in adults with topical fluticasone propionate. Br J Dermatol 1999 140 : 1115 21.
22. Hanifin J, Gupta AK, Rajagopalan R. Intermittent dosing of fluticasone propionate cream for reducing the risk of relapse in atopic dermatitis patients. Br J Dermatol 2002 147 : 528 37.
23. Eichenfield LF, Hanifin JM, Beck LA et al. Atopic dermatitis and asthma: parallels in the evolution of treatment. Pediatrics 2003 111 : 608 16.
24. Faergemann J, Christensen O, Sjovall P et al. An open study of efficacy and safety of long-term treatment with mometasone furoate fatty cream in the treatment of adult patients with atopic dermatitis. J Eur Acad Dermatol Venereol 2000 14 : 393 6.
25. Veien NK, Olhom Larsen P, Thestrup-Pedersen K, Schou G. Long-term intermittent treatment of chronic hand eczema with mometasone furoate. Br J Dermatol 1999 140 : 882 6.
26. Steinhoff M, Bienenstock J, Schmelz M et al. Neurophysiological, neuroimmunological, and neuroendocrine basis of pruritus. J Invest Dermatol 2006 126 : 1705 18.
27. Hamid Q, Naseer T, Minshall EM et al. In vivo expression of IL-12 and IL-13 in atopic dermatitis. J Allergy Clin Immunol 1996 98 : 225 31.
28. Wakugawa M, Hayashi K, Nakamura K, Tamaki K. Evaluation of mite-allergen induced Th1 and Th2 cytokine secretion of peripheral blood mononuclear cells from atopic dermatitis patients: association between IL-13 and mite-specific IgE levels. J Dermatol Sci 2001 25 : 116 26.
29. Sonkoly E, Muller A, Lauerma A et al. IL-31: a new link between T cells and pruritus in atopic skin inflammation. J Allergy Clin Immunol 2006 117 : 411 17.